Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression

Clinical Cancer Research

Volumn 5, Issue 8, 1999, Pages 2082-2088

  Osman, Iman ^a   Drobnjak, Marija ^a   Fazzari, Melissa ^a   Ferrara, Joseph ^a   Scher, Howard I ^a   Cordon Cardo, Carlos ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53;

ARTICLE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SIGNAL TRANSDUCTION; TUMOR GROWTH;

AGED; CELL DIVISION; CELL NUCLEUS; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECURRENCE; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032772364     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Cordon-Cardo, C. Mutation of cell cycle regulators. Biological and clinical implication for human neoplasms. Am. J. Pathol., 147: 545-560, 1995.
2. Momand, J., Zambetti, G. P., Olsen, D. C., George, D. L., and Levine, A J. The MDM2 oncogene products forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
3. Lianes, P., Orlow, I., Zhang, Z-F., Oliva, M., Sarkis, A., Reuter, V., and Cordon-Cardo, C. Altered patterns of MDM2 and TP53 expression in human bladder cancer J. Natl. Cancer Inst., 86: 1325-1330, 1994.
4. Gorgoulis, V. G., Rassidakis, G. Z., Karameris, A. M., Papastamatiou, H., Trigidou, R., Veslemes, M., Rassidakis, A. N., and Kittas, C. Immunohistochemical and molecular evaluation of the mdm2 gene product in bronchogenic carcinoma. Mod. Pathol., 9: 544-554, 1996.
5. Sinicrope, F. A., Roddey, G., Lemoine, M., Ruan, S., Stephens, L. C., Frazier, M. L., Shen, Y., and Zhang, W. Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers. Clin. Cancer Res., 4: 1251-1261, 1998.
6. Lacombe, L., Orlow, I., Zhang, Z-F., Oliva, M., Sarkis, A., Reuter, V. G., and Cordon-Cardo, C. Analysis of p21WAF1/CIP1 in primary bladder tumors. Oncol. Res., 8: 409-414, 1996.
7. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z-F., Sheinfeld, J., Fair, W. R., Herr, H W., and Reuter, V. E. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst., 85: 53-59, 1993
8. Cordon-Cardo, C., Dalbagni, G., Saez, G. T., Oliva, M. R., Zhang, Z-F., Rosai, J., Reuter, V. E., and Pellicer, A. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer, 56: 347-353, 1992.
9. Osman, I., Scher, H. I., Zhang, Z-F., Pellicer, I., Hamza, R., Eissa, S , Khaled, H., and Cordon-Cardo, C. Alterations affecting the p53 control pathway in Bilharzial-related bladder cancer. Clin. Cancer Res., 3: 531-536, 1997.
10. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F., and Levine, A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas Cancer Res., 54: 794-799, 1994.
11. Heslin, M. J., Cordon-Cardo, C., Lewis, J. J., Woodruff, J. M., and Brennan, M. F. Ki67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high-grade extremity soft tissue sarcoma. Cancer (Phila.), 83: 490-497, 1998.
12. Osman, I., Scher, H., Zhang, Z-F., Soos, T. J., Hamza, R., Eissa, S., Khaled, H., Koff, A., and Cordon-Cardo, C. Expression of cyclin D1, but not cyclins E and A, is related to progression in Bilharzial bladder cancer. Clin. Cancer Res., 3: 2247-2251, 1997.
13. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-220, 1972.
14. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
15. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163-170, 1966.
16. Agresti, A. Categorical Data Analysis, pp. 39-44. New York: Wiley, 1996.
17. Hall, M. C., Navone, N. M., Troncoso, P., Pollack, A., Zagars, G. K., von Eschenbach, A. C., Conti, C. J., and Chung, L. W. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology, 45: 470-475, 1995.
18. Kubota, Y., Shuin, T., Uemura, H., Fujinami, K., Miyamoto, H., Torigoe, S., Dobashi, Y., Kitamura, H., Iwasaki, Y., and Danenberg, K. Tumor suppressor gene p53 mutations in human prostate cancer. Prostate, 27: 18-24, 1995.
19. Hughes, J. H., Cohen, M. B., and Robinson, R. A. p53 immunoreactivity in primary and metastatic prostatic adenocarcinoma. Mod. Pathol., 8: 462-466, 1995.
20. Theodorescu, D., Broder, S. R., Boyd, J. C., Mills, S. E., and Frierson, H. F., Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J. Urol., 158: 131-137, 1997.
21. Gumerlock, P. H., Chi, S. G., Shi, X. B., Voeller, H. J., Jacobson, J. W., Gelmann, E. P., and de Vere White, R. W. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J. Natl. Cancer Inst., 89: 66-71, 1997.
22. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., and Moul, J. W. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarker in surgically treated clinically localized prostate cancer. J. Urol., 156: 1511-1516, 1996.
23. Sinik, Z., Alkibay, T., Ataoglu, O., Biri, H., Sozen, S., Deniz, N., Karaoglan, U., and Bozkirli, I. Nuclear p53 overexpression in bladder, prostate, and renal carcinomas. Int. J. Urol., 4: 546-551, 1997.
24. Brooks, J. D., Bova, G. S., Ewing, C. M., Piantadosi, S., Carter, B. S., Robinson, J. C., Epstein, J. I., and Isaacs, W. B. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res., 56: 3814-3822, 1996.
25. Srivastava, S., and Moul, J. W. p53 tumor suppressor gene alteration in prostate cancer and potential gene therapy approaches. Mol. Urol., 1: 151-158, 1997.
26. Kubbutat, M. H. G., Ludwig, R. L., Ashcroft, M. and Vousden, K. H. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol., 18: 5690-5698, 1998.
27. Grossman, S.R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z. X., Kumar, S., Howley, P. M., and Livingston, D. M. p300/ MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell, 2: 405-415, 1998.
28. Ittmann, M., Wieczorek, R., Heller, P., Dave, A., Provet, J., and Krolewski, J. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am. J. Pathol., 145: 287-293, 1994.
29. Capoulade, C., Bressac-de Paillerets, B., Lefrere, I., Ronsin, M., Feunteun, J., Tursz, T., and Wiels, J. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene, 16: 1603-1610, 1998.
30. Bueso-Ramos, C. E., Manshouri, T., Haidar, M. A., Yang, Y., McCown, P., Ordonez, N., Glassman, A., Sneige, N., and Albitar, M. Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res. Treat., 37: 179-188, 1996.
31. 1 to S phase transition in mouse fibroblast and melanoma cells. Biochem. Biophys. Res. Commun., 251: 291-295, 1998.
32. Fan, Z., Shang, B. Y., Lu, Y., Chou, J. L., and Mendelsohn, J. Reciprocal changes in p27 (Kip1) and p21 (Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin. Cancer Res., 3: 1943-1948, 1997.
33. Elbendary, A. A., Cirisano, F. D., Evans, A. C., Jr., Davis, P. L., Iglehart, J. D., Marks, J. R., and Berchuck, A. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin. Cancer Res., 2: 1571-1575, 1996.
34. Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M G., Groshen, S., Taylor, C R., Jones, P. A., Skinner, D. G., and Cote, R. J. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst., 90: 1072-1079, 1998.
35. Valassiadou, K. E., Stefanaki, K., Tzardi, M., Datseris, G., Georgoulias, V., Melissas, J., Tsiftsis, D. D., Delides, G., and Kanavaros, P. Immunohistochemical expression of p53, bcl-2. mdm2 and waf1/p21 proteins in colorectal adenocarcinomas. Anticancer Res., 17: 2571-2576, 1997.
36. Qin, L. F., Ng, I. O., Fan, S. T., and Ng, M. p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int. J. Cancer, 79: 424-428, 1998.
37. Caffo, O., Doglioni, C., Veronese, S., Bonzanini, M., Marchetti, A., Buttitta, F., Fina, P., Leek, R., Morelli, L., Palma, P. D., Harris, A. L., and Barbareschi, M. Prognostic value of p21 (WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res., 2: 1591-1599, 1996.
38. Sarbia, M., Stahl, M., Hausen, A. Z., Zimmermann, K., Wang, L., Fink, U., Heep, H., Dutkowski, P., Willers, R., Muller, W., Seeber, S., and Gabbert, H. Expression of p21 predicts outcome of esophageal cancer patients treated by surgery alone or by combination therapy modalities. Clin. Cancer Res., 4: 2615-2623, 1998.
39. Erber, R., Klein, W., Andl, T., Enders, C., Born, A. I., Conradt, C., Bartek, J., and Bosch, F. X. Aberrant p21 (CIP1/WAF1) protein accumulation in head and neck cancer. Int. J. Cancer, 74: 383-389, 1997.
40. Zhang, W., Kornblau, S. M., Kobayashi, T., Gambel, A., Claxton, D., and Deisseroth, A. B. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin. Cancer Res., 1: 1051-1057, 1995.
41. Ruan, S., Okcu, M. F., Ren, J. P., Chiao, P., Andreeff, M., Levin, V., and Zhang, W. Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res., 58: 1538-1543, 1998.
42. Tanaka, A., Furuya, A., Yamasaki, M., Hanai, N., Kuriki, K., Kamiakito, T., Kobayashi, Y., Yoshida, H., Koike, M., and Fukayama, M. High frequency of fibroblast growth factor (FGF) 8 expression m clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res., 58: 2053-2056, 1998.
43. Peehl, D. M., and Sellers, R. G. Basic FGF, EGF, and PDGF modify TGF β-induction of smooth muscle cell phenotype in human prostatic stromal cells. Prostate, 35: 125-134, 1998.
44. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Hittmair, A., Zhang, J., Thurnher, M., Bartsch, G., and Klocker, H. Regulation of prostatic growth and function by peptide growth factors. Prostate, 28: 392-405, 1996.
45. Scher, H. I., Sarkis, A., Reuter, V., Cohen, D., Netto, G., Petrylak, D., Lianes, P., Fuks, Z., Mendelson, J., and Cordon-Cardo, C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor a in the progression of prostatic neoplasms. Clin. Cancer Res., 1: 545-550, 1995.
46. Cohen, D. W., Simak, R., Fair, W. R., Melamed, J., Scher, H. I., and Cordon-Cardo, C. Expression of transforming growth factor-α and the epidermal growth factor receptor in human prostate tissues. J. Urol., 152: 2120-2124, 1994.